Table 3.
Adverse Events(grade ≥ 3) | CHOP-R(n = 263) |
CHOP-RIT(n = 263) |
P | ||
---|---|---|---|---|---|
No. of Patients | % | No. of Patients | % | ||
Neutropenia | 127 | 48 | 135 | 51 | .54 |
Thrombocytopenia | 6 | 2 | 46 | 18 | < .0001 |
Anemia | 7 | 3 | 8 | 3 | 1.00 |
Infection | 61 | 23 | 45 | 17 | .10 |
Febrile neutropenia | 42 | 16 | 26 | 10 | .05 |
Gastrointestinal | 20 | 8 | 24 | 9 | .64 |
Cardiovascular | 19 | 7 | 9 | 3 | .08 |
Fatigue | 11 | 4 | 9 | 3 | .82 |
Grade 4 nonhematologic | 14 | 5 | 11 | 4 | .68 |
Treatment-related deaths | 1 | < 1 | 4 | 2 | .37 |
Second malignancies | 23 | 9 | 22 | 8 | 1.00 |
AML/MDS | 3 | 1 | 8 | 3 | .22 |
Abbreviations: AML/MDS, acute myeloid leukemia/myelodysplastic syndrome; CHOP-R, cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab; CHOP-RIT, cyclophosphamide, doxorubicin, vincristine, prednisone with tositumomab/iodine I-131 tositumomab radioimmunotherapy.